Figure 1.
Figure 1. Overall survival by randomized dose calculated for all patients and censored at date of stem cell transplantation or start of imatinib in chronic phase. Solid line indicates high-dose IFN-alfa (5 MIU/m2 daily); dotted line, low-dose IFN-alfa (3 MIU 5 times a week). (A) All patients. (B) Patients censored at date of stem cell transplantation or the start of imatinib.

Overall survival by randomized dose calculated for all patients and censored at date of stem cell transplantation or start of imatinib in chronic phase. Solid line indicates high-dose IFN-alfa (5 MIU/m2 daily); dotted line, low-dose IFN-alfa (3 MIU 5 times a week). (A) All patients. (B) Patients censored at date of stem cell transplantation or the start of imatinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal